Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor)

被引：0
|
作者：
Borg, C. [1 ]
Delord, J. P. [2 ]
Husseini, F. [3 ]
Lenoir, V. Trillet [4 ]
Faroux, R.
Francois, E. [5 ]
Ychou, M. [6 ]
Bergougnoux, L. [7 ]
Bennouna, J. [8 ]
Douillard, J. Y. [8 ]
机构：
[1] CHU Besancon, INSERM, U 645, Toulouse, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Hop Louis Pasteur, Colmar, France
[4] Ctr Hosp Lyon Sud, Lyon, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] CHRU, Montpellier, France
[7] Dept Stat, Neuilly sur Seine, France
[8] Ctr Rene Gauducheau, F-44035 Nantes, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70998-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3070
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [1] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
    Bennouna, Jaafar
    Borg, Christophe
    Delord, Jean-Pierre
    Husseini, Faress
    Trillet-Lenoir, Veronique
    Faroux, Roger
    Francois, Eric
    Ychou, Marc
    Goldwasser, Francois
    Bouche, Olivier
    Senellart, Helene
    Kraemer, Sandrine
    Douillard, Jean-Yves
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
  • [2] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
  • [3] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [4] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [5] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [6] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
  • [7] Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
    Tang, Patricia A.
    Cohen, Steven J.
    Kollmannsberger, Christian
    Bjarnason, Georg
    Virik, Kiran
    MacKenzie, Mary J.
    Lourenco, Lillian
    Wang, Lisa
    Chen, Alice
    Moore, Malcolm J.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6023 - 6031
  • [8] Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study
    Bennouna, J.
    Husseini, F.
    Delord, J. P.
    Borg, C.
    Trillet-Lenoir, V.
    Faroux, R.
    Francois, E.
    Ychou, M.
    Chaaban, B.
    Douillard, J. Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 344
  • [9] Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
    Reddy, S. M.
    Kopetz, S.
    Morris, J.
    Parikh, N.
    Qiao, W.
    Overman, M. J.
    Fogelman, D.
    Shureiqi, I.
    Jacobs, C.
    Malik, Z.
    Jimenez, C. A.
    Wolff, R. A.
    Abbruzzese, J. L.
    Gallick, G.
    Eng, C.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 977 - 984
  • [10] Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer
    Mermershtain, W
    Lavrenkov, K
    Cohen, Y
    JOURNAL OF CHEMOTHERAPY, 2000, 12 (02) : 183 - 185
12345